Targeting ACVRL1, dubbed an 'overlooked' gene by researchers, could potentially lead to new treatments for IPF, a study suggests.

Columnist Sam Kirton talks to two members of the Pulmonary Fibrosis Foundation, who explain how its strategic plan can aid the PF community.

Treatment with Esbriet, a drug approved for people with idiopathic pulmonary fibrosis, was found to ease heart stiffness and rhythm issues.

Every person with idiopathic pulmonary fibrosis experiences it differently, making each patient's journey unique, says columnist Sam Kirton.

The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring ...

Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in an early Phase 2a clinical trial, according to new data ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due to safety issues. The BEACON-IPF (NCT06097260) ...

On New Year’s Day, my daughters and I created vision boards for 2026. If you haven’t made one before, a vision board is a collage of images, quotes, and art that captures your goals and intentions for ...

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...